Traders should anticipate near-term downward pressure on the stock due to dilution; monitor for insider selling or short interest changes. The capital raise extends the runway for SAB-142 development, but lack of near-term catalysts may limit upside until clinical data releases.
SABS drugs
SABS drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 18 $3.70entry
- T+1 · 8mo ago +2.16%α +2.43% · $3.78
- T+5 · 8mo ago +3.24%α +3.96% · $3.82
- T+20 · 7mo ago +5.95%α −0.10% · $3.92
- T+60 · 5mo ago −8.65%α −20.17% · $3.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SAB Biotherapeutics (SABS) announced the pricing of a public offering, selling 19.3 million shares at $3.85 and pre-funded warrants for 2.8 million shares at $3.8499, raising approximately $85 million in gross proceeds. The funds will primarily support clinical development of its lead candidate, SAB-142, for type 1 diabetes. The offering includes a 30-day underwriter option to purchase up to an additional 3.3 million shares.
Key Financial Metrics
Key Facts
- SAB Biotherapeutics is raising approximately $85 million through a public offering of common stock and pre-funded warrants.
- 19,324,677 shares priced at $3.85 per share; pre-funded warrants for 2,753,246 shares priced at $3.8499.
- Underwriters have a 30-day option to purchase up to 3,311,688 additional shares.
- Proceeds will fund development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes.
- The offering is expected to close on or about March 19, 2026, subject to customary conditions.
Financial Impact
$85 million gross proceeds, with significant dilution from ~19.3M new shares and ~2.8M pre-funded warrants; underwriters may add ~3.3M more shares.
Risk Factors
- Significant shareholder dilution from issuance of over 22 million shares (including warrants and potential over-allotment).
- Biotech clinical-stage risk: SAB-142 is still in Phase 2b with no guarantee of success.
- Market conditions could delay or alter the final closing terms, though pricing is already set.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257861 |
Track record
15 reports on SABS
3 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $2.94 Now $3.00 +2.04% settles Dec 4
- Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
- Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
- Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
- Jul 7, 202618w ago 8-K Bullish 4/10 Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
- May 29, 202624w ago Press Release Neutral 3/10 Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
- May 12, 202626w ago Press Release Bearish 7/10 Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers